Close
Digital Health & Ai Innovation summit 2026
APE 2026

Multidisciplinary prostate cancer experts at PROSCA

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Konica Minolta and deepc AI Partnership...

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed...

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand...

Novartis, which is a world-leading innovative medicines company, has...
Prostate cancer management is not a solo trip.There are a lot of people involved and there is never just one solution.
Multidisciplinarity is key in prostate cancer management throughout the spectrum of the disease. A patient seen by a multidisciplinary team is more likely to receive a balanced perspective on the risks and benefits of all available options. From low-risk disease where both urologists and radiation oncologist are involved to advanced PCa where medical oncologists join the team.

Next to the treating physicians, supportive physicians such as pathologists and radiologists and allied healthcare professionals such as nurse specialists and pharmacists have an important role in the multidisciplanry team. 

It’s key to us that the faculty and the participants form a fusion of disciplines who can learn from each other.

Latest stories

Related stories

Konica Minolta and deepc AI Partnership Expands Exa Platform

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed Go Smart MDI System

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand Therapy Facility

Novartis, which is a world-leading innovative medicines company, has...

Tempus-NYU Langone Collaboration Advances Precision Oncology

Tempus and NYU Langone Health have signed a multi-year...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »